Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stock Competitors & Peer Comparison
See REGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for REGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| REGN | $827.72 | -1.87% | 85.3B | 18.14 | $45.63 | +0.45% |
| VRTX | $546.12 | -2.12% | 138.6B | 28.70 | $19.03 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,033.15 | -1.93% | 64.2B | 93.24 | $11.08 | N/A |
| MRNA | $145.55 | -2.23% | 57.8B | -17.86 | -$8.15 | N/A |
| RVMDW | $11.70 | -2.34% | 46.7B | -1.65 | -$7.21 | N/A |
| RVMD | $210.02 | -0.40% | 44.6B | -23.81 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.26 | -1.22% | 38.3B | 63.04 | $5.68 | N/A |
| ALNY | $266.11 | +0.61% | 35.6B | 47.95 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
REGN vs VRTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while VRTX trades at $546.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas VRTX's P/E ratio is 28.70. In terms of profitability, REGN's ROE is +0.14%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, REGN is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
REGN vs VRNA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, REGN's ROE is +0.14%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, REGN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
REGN vs ARGX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ARGX trades at $1,033.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ARGX's P/E ratio is 93.24. In terms of profitability, REGN's ROE is +0.14%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, REGN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
REGN vs MRNA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MRNA has a market cap of 57.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MRNA trades at $145.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MRNA's P/E ratio is -17.86. In terms of profitability, REGN's ROE is +0.14%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, REGN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
REGN vs RVMDW Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RVMDW trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RVMDW's P/E ratio is -1.65. In terms of profitability, REGN's ROE is +0.14%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, REGN is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
REGN vs RVMD Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RVMD has a market cap of 44.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RVMD trades at $210.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RVMD's P/E ratio is -23.81. In terms of profitability, REGN's ROE is +0.14%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, REGN is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
REGN vs SGEN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, REGN's ROE is +0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, REGN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
REGN vs ONC Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ONC trades at $358.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ONC's P/E ratio is 63.04. In terms of profitability, REGN's ROE is +0.14%, compared to ONC's ROE of +0.14%. Regarding short-term risk, REGN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
REGN vs ALNY Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ALNY trades at $266.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ALNY's P/E ratio is 47.95. In terms of profitability, REGN's ROE is +0.14%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, REGN is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
REGN vs INSM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, INSM has a market cap of 27.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while INSM trades at $126.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas INSM's P/E ratio is -30.73. In terms of profitability, REGN's ROE is +0.14%, compared to INSM's ROE of -1.11%. Regarding short-term risk, REGN is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
REGN vs BNTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BNTX has a market cap of 26.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BNTX trades at $103.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BNTX's P/E ratio is -13.46. In terms of profitability, REGN's ROE is +0.14%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, REGN is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
REGN vs INCY Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, INCY has a market cap of 25.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while INCY trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas INCY's P/E ratio is 17.04. In terms of profitability, REGN's ROE is +0.14%, compared to INCY's ROE of +0.30%. Regarding short-term risk, REGN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for REGN.Check INCY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
REGN vs ROIV Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ROIV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ROIV's P/E ratio is -33.23. In terms of profitability, REGN's ROE is +0.14%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, REGN is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
REGN vs UTHR Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, UTHR has a market cap of 20.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while UTHR trades at $487.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas UTHR's P/E ratio is 17.45. In terms of profitability, REGN's ROE is +0.14%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, REGN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
REGN vs GMAB Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, GMAB has a market cap of 20.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while GMAB trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas GMAB's P/E ratio is 25.32. In terms of profitability, REGN's ROE is +0.14%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, REGN is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for REGN.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
REGN vs BGNE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, REGN's ROE is +0.14%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, REGN is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
REGN vs DNA-WT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, REGN is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
REGN vs ASND Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ASND trades at $270.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ASND's P/E ratio is -111.80. In terms of profitability, REGN's ROE is +0.14%, compared to ASND's ROE of +1.90%. Regarding short-term risk, REGN is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
REGN vs NBIX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while NBIX trades at $155.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas NBIX's P/E ratio is 22.49. In terms of profitability, REGN's ROE is +0.14%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, REGN is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
REGN vs JAZZ Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while JAZZ trades at $246.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas JAZZ's P/E ratio is 9.23. In terms of profitability, REGN's ROE is +0.14%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, REGN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for REGN.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
REGN vs EXEL Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while EXEL trades at $59.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas EXEL's P/E ratio is 16.86. In terms of profitability, REGN's ROE is +0.14%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, REGN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for REGN.Check EXEL's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
REGN vs BBIO Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BBIO trades at $74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BBIO's P/E ratio is -20.01. In terms of profitability, REGN's ROE is +0.14%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, REGN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
REGN vs SMMT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while SMMT trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas SMMT's P/E ratio is -15.72. In terms of profitability, REGN's ROE is +0.14%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, REGN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
REGN vs HALO Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while HALO trades at $110.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas HALO's P/E ratio is 20.56. In terms of profitability, REGN's ROE is +0.14%, compared to HALO's ROE of +1.81%. Regarding short-term risk, REGN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for REGN.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
REGN vs BMRN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BMRN trades at $66.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BMRN's P/E ratio is 31.99. In terms of profitability, REGN's ROE is +0.14%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, REGN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
REGN vs KRTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, REGN's ROE is +0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, REGN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
REGN vs MDGL Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MDGL trades at $541.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MDGL's P/E ratio is -42.27. In terms of profitability, REGN's ROE is +0.14%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, REGN is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
REGN vs ARWR Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ARWR trades at $86.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ARWR's P/E ratio is -38.37. In terms of profitability, REGN's ROE is +0.14%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, REGN is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
REGN vs TECH Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TECH trades at $72.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TECH's P/E ratio is 37.34. In terms of profitability, REGN's ROE is +0.14%, compared to TECH's ROE of +0.09%. Regarding short-term risk, REGN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
REGN vs RNAM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, REGN's ROE is +0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, REGN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
REGN vs AXSM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while AXSM trades at $206.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas AXSM's P/E ratio is -53.96. In terms of profitability, REGN's ROE is +0.14%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, REGN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
REGN vs KRYS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while KRYS trades at $358.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas KRYS's P/E ratio is 44.89. In terms of profitability, REGN's ROE is +0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, REGN is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
REGN vs PRAX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PRAX has a market cap of 9.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PRAX trades at $351.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PRAX's P/E ratio is -27.21. In terms of profitability, REGN's ROE is +0.14%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, REGN is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
REGN vs KYMR Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas KYMR's P/E ratio is -36.68. In terms of profitability, REGN's ROE is +0.14%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, REGN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for REGN.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
REGN vs IONS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, IONS has a market cap of 9.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while IONS trades at $58.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas IONS's P/E ratio is -33.77. In terms of profitability, REGN's ROE is +0.14%, compared to IONS's ROE of -1.11%. Regarding short-term risk, REGN is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IONS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
REGN vs RXDX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, REGN's ROE is +0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
REGN vs PTGX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PTGX trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PTGX's P/E ratio is 141.48. In terms of profitability, REGN's ROE is +0.14%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, REGN is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
REGN vs NUVL Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas NUVL's P/E ratio is -21.79. In terms of profitability, REGN's ROE is +0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, REGN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for REGN.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
REGN vs CYTK Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CYTK trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CYTK's P/E ratio is -10.07. In terms of profitability, REGN's ROE is +0.14%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, REGN is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
REGN vs CRNX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CRNX's P/E ratio is -16.86. In terms of profitability, REGN's ROE is +0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, REGN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
REGN vs PCVX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PCVX trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PCVX's P/E ratio is -8.02. In terms of profitability, REGN's ROE is +0.14%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, REGN is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
REGN vs IMGN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, REGN's ROE is +0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, REGN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
REGN vs TGTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TGTX trades at $55.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TGTX's P/E ratio is 20.28. In terms of profitability, REGN's ROE is +0.14%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, REGN is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
REGN vs IBRX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while IBRX trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas IBRX's P/E ratio is -8.33. In terms of profitability, REGN's ROE is +0.14%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, REGN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IBRX's competition here
Abivax S.A. (NASDAQ: ABVX)
REGN vs ABVX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ABVX trades at $114.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ABVX's P/E ratio is -60.17. In terms of profitability, REGN's ROE is +0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, REGN is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
REGN vs BPMC Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, REGN's ROE is +0.14%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, REGN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for REGN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
REGN vs APGE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas APGE's P/E ratio is -31.19. In terms of profitability, REGN's ROE is +0.14%, compared to APGE's ROE of -0.30%. Regarding short-term risk, REGN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
REGN vs CERE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, REGN's ROE is +0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, REGN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
REGN vs IMVT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while IMVT trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas IMVT's P/E ratio is -13.92. In terms of profitability, REGN's ROE is +0.14%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, REGN is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
REGN vs TXG Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TXG has a market cap of 8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TXG trades at $62.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TXG's P/E ratio is -106.19. In terms of profitability, REGN's ROE is +0.14%, compared to TXG's ROE of -0.09%. Regarding short-term risk, REGN is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
REGN vs TWST Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TWST trades at $124.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TWST's P/E ratio is -56.18. In terms of profitability, REGN's ROE is +0.14%, compared to TWST's ROE of -0.30%. Regarding short-term risk, REGN is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TWST's competition here
Belite Bio, Inc (NASDAQ: BLTE)
REGN vs BLTE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, BLTE has a market cap of 7.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while BLTE trades at $193.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas BLTE's P/E ratio is -103.53. In terms of profitability, REGN's ROE is +0.14%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, REGN is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check BLTE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
REGN vs SYRE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while SYRE trades at $88.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas SYRE's P/E ratio is -45.63. In terms of profitability, REGN's ROE is +0.14%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, REGN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
REGN vs MTSR Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, REGN's ROE is +0.14%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, REGN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
REGN vs CAI Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CAI trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CAI's P/E ratio is 70.44. In terms of profitability, REGN's ROE is +0.14%, compared to CAI's ROE of +0.19%. Regarding short-term risk, REGN is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
REGN vs RYTM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RYTM trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RYTM's P/E ratio is -33.04. In terms of profitability, REGN's ROE is +0.14%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, REGN is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
REGN vs MRUS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, REGN's ROE is +0.14%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, REGN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
REGN vs ACLX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ACLX's P/E ratio is -28.27. In terms of profitability, REGN's ROE is +0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, REGN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
REGN vs SRRK Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while SRRK trades at $55.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas SRRK's P/E ratio is -16.04. In terms of profitability, REGN's ROE is +0.14%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, REGN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for REGN.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
REGN vs CGON Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CGON trades at $74.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CGON's P/E ratio is -27.76. In terms of profitability, REGN's ROE is +0.14%, compared to CGON's ROE of -0.25%. Regarding short-term risk, REGN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
REGN vs RETA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, REGN's ROE is +0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, REGN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
REGN vs CNTA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CNTA's P/E ratio is -22.63. In terms of profitability, REGN's ROE is +0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, REGN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
REGN vs MIRM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MIRM trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MIRM's P/E ratio is -6.93. In terms of profitability, REGN's ROE is +0.14%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, REGN is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MIRM's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
REGN vs TVTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TVTX trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TVTX's P/E ratio is -145.07. In terms of profitability, REGN's ROE is +0.14%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, REGN is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
REGN vs DNTH Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while DNTH trades at $108.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas DNTH's P/E ratio is -26.05. In terms of profitability, REGN's ROE is +0.14%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, REGN is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
REGN vs COGT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while COGT trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas COGT's P/E ratio is -16.47. In terms of profitability, REGN's ROE is +0.14%, compared to COGT's ROE of -0.73%. Regarding short-term risk, REGN is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
REGN vs PTCT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PTCT trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PTCT's P/E ratio is -29.74. In terms of profitability, REGN's ROE is +0.14%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, REGN is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PTCT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
REGN vs XENE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while XENE trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas XENE's P/E ratio is -12.71. In terms of profitability, REGN's ROE is +0.14%, compared to XENE's ROE of -0.44%. Regarding short-term risk, REGN is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
REGN vs LGND Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while LGND trades at $285.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas LGND's P/E ratio is 31.35. In terms of profitability, REGN's ROE is +0.14%, compared to LGND's ROE of +0.20%. Regarding short-term risk, REGN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for REGN.Check LGND's competition here
Erasca, Inc. (NASDAQ: ERAS)
REGN vs ERAS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ERAS trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ERAS's P/E ratio is -17.41. In terms of profitability, REGN's ROE is +0.14%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, REGN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ERAS's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
REGN vs CDTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, REGN's ROE is +0.14%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, REGN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
REGN vs ORKA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ORKA trades at $92.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ORKA's P/E ratio is -47.69. In terms of profitability, REGN's ROE is +0.14%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, REGN is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
REGN vs ABCM Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, REGN's ROE is +0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, REGN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
REGN vs ISEE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, REGN's ROE is +0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, REGN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
REGN vs CRSP Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CRSP trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CRSP's P/E ratio is -11.72. In terms of profitability, REGN's ROE is +0.14%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, REGN is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
REGN vs APLS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas APLS's P/E ratio is 38.35. In terms of profitability, REGN's ROE is +0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, REGN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for REGN.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
REGN vs DFTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while DFTX trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas DFTX's P/E ratio is N/A. In terms of profitability, REGN's ROE is +0.14%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, REGN is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DFTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
REGN vs ACAD Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ACAD trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ACAD's P/E ratio is 12.62. In terms of profitability, REGN's ROE is +0.14%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, REGN is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
REGN vs TERN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TERN's P/E ratio is -51.41. In terms of profitability, REGN's ROE is +0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, REGN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TERN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
REGN vs PBLS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PBLS has a market cap of 4.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PBLS trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PBLS's P/E ratio is -45.93. In terms of profitability, REGN's ROE is +0.14%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, REGN is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PBLS's competition here
Celcuity Inc. (NASDAQ: CELC)
REGN vs CELC Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CELC trades at $95.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CELC's P/E ratio is -22.26. In terms of profitability, REGN's ROE is +0.14%, compared to CELC's ROE of -3.51%. Regarding short-term risk, REGN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
REGN vs EWTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while EWTX trades at $43.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas EWTX's P/E ratio is -23.28. In terms of profitability, REGN's ROE is +0.14%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, REGN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
REGN vs FOLD Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas FOLD's P/E ratio is -161.00. In terms of profitability, REGN's ROE is +0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, REGN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for REGN.Check FOLD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
REGN vs DYN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, DYN has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while DYN trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas DYN's P/E ratio is -7.54. In terms of profitability, REGN's ROE is +0.14%, compared to DYN's ROE of -0.64%. Regarding short-term risk, REGN is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check DYN's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
REGN vs AKRO Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, REGN's ROE is +0.14%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, REGN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for REGN.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
REGN vs ALPN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, REGN's ROE is +0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, REGN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
REGN vs ELVN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ELVN trades at $59.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ELVN's P/E ratio is -35.52. In terms of profitability, REGN's ROE is +0.14%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, REGN is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for REGN.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
REGN vs OPT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, REGN's ROE is +0.14%, compared to OPT's ROE of +1.18%. Regarding short-term risk, REGN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for REGN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
REGN vs PRTC Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas PRTC's P/E ratio is -3.78. In terms of profitability, REGN's ROE is +0.14%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, REGN is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for REGN.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
REGN vs RLAY Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while RLAY trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas RLAY's P/E ratio is -12.13. In terms of profitability, REGN's ROE is +0.14%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, REGN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for REGN.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
REGN vs MRTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, REGN's ROE is +0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, REGN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
REGN vs MANE Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while MANE trades at $98.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas MANE's P/E ratio is -31.34. In terms of profitability, REGN's ROE is +0.14%, compared to MANE's ROE of -0.29%. Regarding short-term risk, REGN is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for REGN.Check MANE's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
REGN vs VKTX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas VKTX's P/E ratio is -7.48. In terms of profitability, REGN's ROE is +0.14%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, REGN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for REGN.Check VKTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
REGN vs TLX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TLX trades at $11.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TLX's P/E ratio is 124.63. In terms of profitability, REGN's ROE is +0.14%, compared to TLX's ROE of +0.07%. Regarding short-term risk, REGN is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check TLX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
REGN vs LEGN Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while LEGN trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas LEGN's P/E ratio is -31.65. In terms of profitability, REGN's ROE is +0.14%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, REGN is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for REGN.Check LEGN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
REGN vs IOVA Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, IOVA has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while IOVA trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas IOVA's P/E ratio is -12.04. In terms of profitability, REGN's ROE is +0.14%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, REGN is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for REGN.Check IOVA's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
REGN vs TARS Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, TARS has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while TARS trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas TARS's P/E ratio is -83.28. In terms of profitability, REGN's ROE is +0.14%, compared to TARS's ROE of -0.14%. Regarding short-term risk, REGN is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for REGN.Check TARS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
REGN vs ADPT Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while ADPT trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas ADPT's P/E ratio is -59.22. In terms of profitability, REGN's ROE is +0.14%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, REGN is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for REGN.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
REGN vs CPRX Comparison September 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, REGN stands at 85.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, REGN is priced at $827.72 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
REGN currently has a P/E ratio of 18.14, whereas CPRX's P/E ratio is 12.30. In terms of profitability, REGN's ROE is +0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, REGN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for REGN.Check CPRX's competition here